| 000 | 01619 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516224508.0 | ||
| 264 | 0 | _c20151229 | |
| 008 | 201512s 0 0 eng d | ||
| 022 | _a1477-0970 | ||
| 024 | 7 |
_a10.1177/1352458514543340 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHuppke, Peter | |
| 245 | 0 | 0 |
_aJC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity. _h[electronic resource] |
| 260 |
_bMultiple sclerosis (Houndmills, Basingstoke, England) _cApr 2015 |
||
| 300 |
_a382-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAntibodies, Viral _xblood |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
| 650 | 0 | 4 | _aJC Virus |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 |
_aNatalizumab _xtherapeutic use |
| 650 | 0 | 4 |
_aPolyomavirus Infections _xepidemiology |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aSeroconversion |
| 650 | 0 | 4 | _aSeroepidemiologic Studies |
| 700 | 1 | _aHummel, Hanna | |
| 700 | 1 | _aEllenberger, David | |
| 700 | 1 | _aPfeifenbring, Sabine | |
| 700 | 1 | _aStark, Wiebke | |
| 700 | 1 | _aHuppke, Brenda | |
| 700 | 1 | _aBrück, Wolfgang | |
| 700 | 1 | _aGärtner, Jutta | |
| 773 | 0 |
_tMultiple sclerosis (Houndmills, Basingstoke, England) _gvol. 21 _gno. 4 _gp. 382-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/1352458514543340 _zAvailable from publisher's website |
| 999 |
_c24049957 _d24049957 |
||